Volodymyr Pankiv

Prof. Dr. Volodymyr Pankiv

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Arterial Hypertension
Verified
Journal Article
Open access
PDF file
SKSergiy M. Koval
Sergiy M. Koval
KYKostiantyn O. Yushko
Kostiantyn O. Yushko
ISIryna O. Snihurska
Iryna O. Snihurska
TSTetyana G. Starchenko
Tetyana G. Starchenko
VPVolodymyr Pankiv
Volodymyr Pankiv
OMOlga V. Mysnychenko
Olga V. Mysnychenko
Background. The angiotensin-(1-7) is a new component of the renin-angiotensin system, the product of the degradation of angiotensin II and its functional antagonist, but its role in hypertension with type 2 diabetes (T2D) is not clear. The aim of the study was to investigate the levels of angiotensin-(1-7) in patients with hypertension and T2D and determine its relations to hemodynamic and cardiac structural and functional parameters. Material and methods. We examined 70 patients with hypertension and T2D. Investigation protocol included physical examination, standard transthoracic echocardiography and determination of the angiotensin-(1-7) blood levels by ELISA. Control group consisted of 16 healthy volunteers. Results. The angiotensin-(1-7) levels in observed patients were significantly lower than in volunteers [105.51 (89.13;121.17) ng/L vs. 132.75 (125.06; 142.87) ng/L, p < 0.001]. The levels of the angiotensin-(1-7) significantly negatively correlated with duration of hypertension (r = –0.29, p < 0.05), systolic blood pressure (BP) (r = –0.38, p < 0.05), diastolic BP (r = –0.36, p < 0.01), average BP (r = –0.32, p < 0.01), left ventricular (LV) internal dimension at end-diastole (r = –0.37, p < 0.01), LV mass (r = –0.40, p < 0.001), LV mass index (r = –0.41, p < 0.001). In patients with LV hypertrophy, angiotensin-(1-7) levels were significantly lower than in patients without LV hypertrophy [101.9 (88.2; 117.7) ng/L vs. 129.3 (117.5; 136.8) ng/L, p < 0.01] and in patients with diastolic LV dysfunction — lower than in the patients with normal diastolic function [101.1 (87.9; 116.6) ng/L vs. 121.1 (105.5; 128.9) ng/L, p < 0.01]. Conclusions. The angiotensin-(1-7) can be considered as an important pathogenetic factor in the development of hypertension with T2D, a BP regulator and a cardioprotective agent that prevents the development of remodeling and diastolic dysfunction of the LV. Background. The angiotensin-(1-7) is a new component of the renin-angiotensin system, the product of the degradation of angiotensin II and its functional antagonist, but its role in hypertension with type 2 diabetes (T2D) is not clear. The aim of the study was to investigate the levels of angiotensin-(1-7) in patients with hypertension and T2D and determine its relations to hemodynamic and cardiac structural and functional parameters. Material and methods. We examined 70 patients with hypertension and T2D. Investigation protocol included physical examination, standard transthoracic echocardiography and determination of the angiotensin-(1-7) blood levels by ELISA. Control group consisted of 16 healthy volunteers. Results. The angiotensin-(1-7) levels in observed patients were significantly lower than in volunteers [105.51 (89.13;121.17) ng/L vs. 132.75 (125.06; 142.87) ng/L, p < 0.001]. The levels of the angiotensin-(1-7) significantly negatively correlated with duration of hypertension (r = –0.29, p < 0.05), systolic blood pressure (BP) (r = –0.38, p < 0.05), diastolic BP (r = –0.36, p < 0.01), average BP (r = –0.32, p < 0.01), left ventricular (LV) internal dimension at end-diastole (r = –0.37, p < 0.01), LV mass (r = –0.40, p < 0.001), LV mass index (r = –0.41, p < 0.001). In patients with LV hypertrophy, angiotensin-(1-7) levels were significantly lower than in patients without LV hypertrophy [101.9 (88.2; 117.7) ng/L vs. 129.3 (117.5; 136.8) ng/L, p < 0.01] and in patients with diastolic LV dysfunction — lower than in the patients with normal diastolic function [101.1 (87.9; 116.6) ng/L vs. 121.1 (105.5; 128.9) ng/L, p < 0.01]. Conclusions. The angiotensin-(1-7) can be considered as an important pathogenetic factor in the development of hypertension with T2D, a BP regulator and a cardioprotective agent that prevents the development of remodeling and diastolic dysfunction of the LV.

16 January 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
NGNataliia Grygorieva
Nataliia Grygorieva
MOMaryan Ostafiychuk
Maryan Ostafiychuk
VKVolodymir Kovalenko
Volodymir Kovalenko
SKSerhiy Komisarenko
Serhiy Komisarenko
TTTetiana Tatarchuk
Tetiana Tatarchuk
SRSvitlana Regeda
Svitlana Regeda
Vitamin D deficiency (VDD) is a global problem, however, there were no Ukrainian guidelines devoted to its screening, prevention, and treatment, which became the reason for the Consensus creation. This article aimed to present the Consensus of Ukrainian experts devoted to VDD management. Following the creation of the multidisciplinary Consensus group, consent on the formation process, drafting and fine-tuning of key recommendations, and two rounds of voting, 14 final recommendations were successfully voted upon. Despite a recent decrease in VDD prevalence in Ukraine, we recommend raising awareness regarding VDD’s importance and improving the strategies for its decline. We recommend screening the serum 25-hydroxyvitamin D (25(OH)D) level in risk groups while maintaining a target concentration of 75–125 nmol/L (30–50 ng/mL). We recommend prophylactic cholecalciferol supplementation (800–2000 IU/d for youthful healthy subjects, and 3000–5000 IU/d for subjects from the risk groups). For a VDD treatment, we recommend a short-term administration of increased doses of cholecalciferol (4000–10,000 IU/d) with 25(OH)D levels monitored after 4–12 weeks of treatment, followed by the use of maintenance doses. Additionally, we recommend assessing serum 25(OH)D levels before antiosteoporotic treatment and providing vitamin D and calcium supplementation throughout the full course of the antiosteoporotic therapy.

30 June 2023 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
NGNataliia Grygorieva
Nataliia Grygorieva
MOMaryan Ostafiychuk
Maryan Ostafiychuk
VKV.M. Kovalenko
V.M. Kovalenko
SKS.V. Komisarenko
S.V. Komisarenko
TTT.F. Tatarchuk
T.F. Tatarchuk
SRSvitlana Regeda
Svitlana Regeda
Background. Vitamin D deficiency (VDD) is widespread in the world; its proportion varies considerably in different populations and depends on many causes. Up to now, there were no National recommendations for the diagnosis, prevention, and treatment of VDD in adults in Ukraine. Their creation became the purpose of this work. Methodology. Consensus was created using the Delphi method, voting was conducted using the SurveyMonkey® platform. After approval of the composition of the Consensus Group, agreement on the order of formation and structure of the Consensus, creation and correction of the main statements, and two voting rounds, the main Consensus statements were formed and were successfully voted on. The 15 authors of the article are 15 experts who participated in the voting. The final 14 Consensus statements are presented in this article. Each statement is preceded by a justification based on high-quality evidence available in the current literature. Results. Despite the reduction of VDD in the Ukrainian population in recent years, experts have recommen­ded increasing the awareness of the medical community and the Ukrainian population about the problem and ways to overcome it, with a screening of the total serum level of 25-hydroxyvitamin D (25(OH)D) in subjects from the groups of risk to achieve the target concentration of 30–50 ng/ml (75–125 nmol/l). To ensure it, we recommend the individual selection of a prophylactic dose of vitamin D (800–2000 IU/d for young healthy persons and 3000–5000 IU/d for patients with diseases and conditions that affect the metabolism of vitamin D). For the treatment of VDD, we recommend short-term intake of higher doses (4000–10,000 IU/d) of vitamin D with control of the 25(OH)D level after 4–12 weeks of treatment and subsequent use of maintenance doses. Also, we re­commend the determination of serum 25(OH)D level before the initiation of antiosteoporotic therapy in patients with osteoporosis and its complications to prevent its ineffectiveness and increase the safety profile.

3 March 2024 in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Verified
Journal Article
Open access
PDF file
ASAlexandr Serhiyenko
Alexandr Serhiyenko
VSV.B. Sehin
V.B. Sehin
VPVolodymyr Pankiv
Volodymyr Pankiv
ASAlexandr Serhiyenko
Alexandr Serhiyenko
Post-traumatic stress disorder (PTSD) and metabolic syndrome (MetS) frequently coexist and share neurobiological and clinical features. In particular, the results of meta-analyses indicate a higher prevalence of MetS in patients with PTSD compared to the general population. PTSD is also a recognized risk factor for MetS. This synchronicity can be partially explained by pathogenetic pathways present in both conditions. These include genetic factors, dysfunction of the hypothalamic-pituitary-adrenal axis, chronic low-grade inflammation, oxidative stress, insulin resistance, and immune dysregulation. Thus, similar mechanisms are involved in the clinical worsening of PTSD and the development of adverse cardiovascular events associated with MetS. Dyssomnias are one of the characteristic clinical features of PTSD. Today, it is believed that posttraumatic circadian rhythm disorders are the core and not a secondary feature of PTSD, which mediate the neurobiological correlates of disorders due to homeostasis imbalance. At the same time, dyssomnias, chronodestruction, and depressive disorders are part of the pathogenesis of insulin resistance, obesity, and MetS. Thus, treatment of dyssomnias is one of the key tasks in the prevention and treatment of comorbid PTSD and MetS. Regulation of sleep processes and circadian rhythms through exogenous intervention, especially with melatonergic drugs, is likely to be a key part of preventing and treating dyssomnias in people who have both PTSD and MetS. The purpose of this review is to analyze the specifics of the relationships between PTSD and MetS, PTSD and dyssomnias, MetS and sleep disorders. We conducted the search in Scopus, Science Direct (from Elsevier), and PubMed, including Medline databases. The key words used were “post-traumatic stress disorder,” “dyssomnias,” “chronodestruction,” and “metabolic syndrome”. The identification of research findings that were not found during online searches involved manual searching of the bibliography of publications.

30 October 2023 in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Verified
Journal Article
Open access
PDF file
VPVolodymyr Pankiv
Volodymyr Pankiv
TYT.YU. Yuzvenko
T.YU. Yuzvenko
Background. Diabetes distress is among potential barriers for people with diabetes mellitus (DM) to reach glycemic goals. Accumulating evidence suggests diabetes distress may be linked to individuals’ emotion regulation capacities. The purpose of this study was to explicate the relationships between variables of glyca­ted hemoglobin (HbA1c), diabetes distress, emotion regulation, and self-care variables through the analysis of cross-sectional data from individuals with type 1 and type 2 DM. Materials and methods. We used structural equation modeling to assess the cross-sectional relationships between variables of HbA1c, diabetes distress, emotion regulation, and self-care variables through the analysis of cross-sectional data from 132 individuals with type 1 and type 2 DM. After giving informed consent for their data to be used for research purposes without identifying them, study participants were examined by clinical psychologists with a structured clinical assessment and a series of other assessments relevant to DM. Results. While participants with type 2 DM differed from those with type 1 DM in terms of age, duration of DM, insulin dependence, and self-care, no significant diffe­rences were observed between the groups in sex, HbA1c levels, diabetes distress, emotion regulation-experience, or emotion regulation-skill scores. Study examined two potential explanatory models with one of them showing a more comprehensive view of the data revealing a total effect of poor emotional regulation on HbA1c levels. Diabetes distress in adults is linked to increased negative emotionality (emotion regulation-experience) and reduced skill at emotional regulation (emotion regulation-skill), both of which are associated with elevated HbA1c levels, and these relationships are stronger than those in diabetes self-care. Conclusions. This study suggests that in people with DM, elevated HbA1c levels and diabetes distress are linked to poor emotion regulation. These data emphasize that targeting difficulties in emotion regulation may hold promise for maximizing improvement in diabetes distress and HbA1c in individuals with DM.

20 March 2025 in INTERNATIONAL NEUROLOGICAL JOURNAL
Verified
Journal Article
Open access
PDF file
ASAlexandr Serhiyenko
Alexandr Serhiyenko
OCO.м. Chemerys
O.м. Chemerys
VPVolodymyr Pankiv
Volodymyr Pankiv
ASAlexandr Serhiyenko
Alexandr Serhiyenko
A person with post-traumatic stress disorder (PTSD) is more likely to develop metabolic syndrome (MetS), depression, and diabetic distress. It also raises the risk of cardiometabolic and neurodegenerative diseases (NDD). At the same time, type 2 diabetes mellitus and MetS can also cause the development of core neurosis-like and psychiatric symptoms characteristic of PTSD. Chronic stress is associated with cardiovascular diseases, type 2 diabetes, and NDD. More and more people think that mitochondrial dysfunction, peripheral/central chronic low-grade inflammation (CLGI), and oxidative stress are the main causes of these diseases. Pathophysiological processes link them together. To make things better for these patients, interventions that aim to control CLGI and oxidative stress may be better, following the ideas of precision medicine. Deficiency of certain biofactors, in particular, vitamin B1, is associated with an increased risk of MetS, type 2 diabetes, cardiovascular diseases, and NDD. Targeted effects on CLGI, oxidative stress, and mitochondrial metabolism disorders suggest that the use of antioxidants, particularly vitamin B1/benfotiamine (BFT), may have a positive effect not only on the course of comorbid diseases but also on the main manifestations of PTSD. Exogenous vitamin B1, or BFT, corrects thiamine status disorders. BFT exhibits potent effects in animal models of NDD, stress-induced anxiety, aggression, and depression. Thus, BFT can be considered a potentially safe and cost-effective drug for the treatment of many central nervous system diseases. Despite its positive aspects, the therapeutic potential of BFT remains limited, as beneficial effects require high doses over a long period of time. Dibenzoylthiamine, a lipophilic form of BFT, has been shown to have anti-inflammatory and antioxidant effects at much lower doses than BFT, both in vitro and in vivo. However, more preclinical and clinical studies are needed to be sure of the clinical viability and therapeutic potential of BFT and dibenzoylthiamine. This review pays extra attention to the analysis of the features of the biological role of vitamin B1, the mechanism of BFT action, especially its impact on glucose metabolism and mitochondrial function, the state of neuroinflammation, and how dibenzoylthiamine can protect neurons. We conducted the search in Scopus, Science Direct (from Elsevier), PubMed, and the MEDLINE databases. The keywords used were “thiamine”, “benfotiamine”, “dibenzoylthiamine”, “post-traumatic stress disorder”, “metabolic syndrome”, “diabetic distress”, and “diabetes mellitus”. We conducted a manual search for the bibliography of publications to pinpoint research results that eluded online search.